CYTK News

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Imbria Pharmaceuticals Receives FDA Orphan Drug Designation for Ninerafaxstat for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program

Cytokinetics bringt MYQORZO® (aficamten) in der Europäischen Union auf den Markt; der erste kommerzielle Vertrieb erfolgt in Deutschland

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

Form 8-K

Cytokinetics to Participate in June Investor Conferences

Cytokinetics to Hold Annual Meeting of Stockholders

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)